Roble, Belko & Company, Inc Applied Therapeutics Inc. Transaction History
Roble, Belko & Company, Inc
- $763 Million
- Q4 2025
A detailed history of Roble, Belko & Company, Inc transactions in Applied Therapeutics Inc. stock. As of the latest transaction made, Roble, Belko & Company, Inc holds 65,571 shares of APLT stock, worth $14,425. This represents 0.0% of its overall portfolio holdings.
Number of Shares
65,571
Previous 30,841
112.61%
Holding current value
$14,425
Previous $19,000
63.16%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding APLT
# of Institutions
78Shares Held
97.7MCall Options Held
357KPut Options Held
301K-
T. Rowe Price Investment Management, Inc. Baltimore, MD21.4MShares$4.71 Million0.01% of portfolio
-
Vestal Point Capital, LP New York, NY14.3MShares$3.14 Million0.39% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA11.3MShares$2.48 Million6.83% of portfolio
-
Knoll Capital Management, LLC Miami, FL7.8MShares$1.72 Million2.64% of portfolio
-
Black Rock Inc. New York, NY6.57MShares$1.45 Million0.0% of portfolio
About Applied Therapeutics Inc.
- Ticker APLT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,020,700
- Market Cap $10.6M
- Description
- Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study...